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RESEARCH ARTICLE Open Access
Reconsidering the prognosis of major
depressive disorder across diagnostic
boundaries: full recovery is the exception
rather than the rule
Judith Verduijn1† , Josine E. Verhoeven1*†, Yuri Milaneschi1, Robert A. Schoevers2, Albert M. van Hemert3,
Aartjan T. F. Beekman1 and Brenda W. J. H. Penninx1
Abstract
Background: Major depressive disorder (MDD) is often handled as an episodic and isolated disorder, resulting in an
optimistic view about its prognosis. Herein, we test the idea that the prognosis of MDD changes if we vary the
perspective in terms of (1) a longer time frame and (2) a broader diagnostic conceptualisation including dysthymia,
(hypo)mania and anxiety disorders as relevant outcomes.
Methods: Patients with current MDD at baseline (n = 903) and available 2-, 4-, and/or 6-year follow-up assessments
were selected from the Netherlands Study of Depression and Anxiety, a psychiatric cohort study. Combining
psychiatric DSM-IV-based diagnoses and life-chart data, patient course trajectories were classified as (1) recovered
(no diagnoses at 2-year follow-up or thereafter), (2) recurrent without chronic episodes, (3) recurrent with chronic
episodes or (4) consistently chronic since baseline. A chronic episode was defined as having a current diagnosis at
the follow-up assessment and consistent symptoms over 2 years. Proportions of course trajectories were provided
moving from a short, narrow perspective (2-year follow-up, considering only MDD diagnosis) to a long, broad
perspective (6-year follow-up, including MDD, dysthymia, (hypo)mania and anxiety diagnoses).
Results: With the short, narrow perspective, the recovery rate was 58% and 21% had a chronic episode. However,
in the long, broad perspective the recovery rate was reduced to 17%, while 55% of the patients experienced
chronic episodes.
Conclusions: Results from a long and rigorous follow-up in a large cohort suggests that most MDD patients have
an unfavourable prognosis. Longer follow-up and broader diagnostic conceptualisation show that the majority of
patients have a disabling and chronic disorder. Conceptualising and handling MDD as a narrowly defined and
episodic disorder may underestimate the prognosis of the majority of depressed patients and, consequently, the
type of care that is appropriate.
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Background
Major depressive disorder (MDD) has been historic-
ally perceived as an episodic disorder. In the early
1900s, Kraepelin differentiated between ‘dementia
praecox’ (now known as schizophrenia), which he
considered chronic and progressive, and ‘(manic)
depression’, which he described as episodic [1, 2]. This
view has ever since dominated our understanding of de-
pression [3–5]. Congruently, longitudinal observational
research over the past century suggests that most MDD
patients eventually recover from their index episode after
relatively short follow-up assessments (e.g. 2 years), and
suggests that, ultimately, only a limited proportion follows
a chronic course [6, 7]. This is further underlined by the
fact that most intervention trial research has stringent
treatment delivery and has focused on the short-term re-
mission of an episode. Moreover, randomised controlled
trials typically include a subset of less severe patients that
have, for example, shorter illness duration and lower rates
of anxious and atypical symptom features [8]. Their
course outcomes might therefore not be representative
and may be more positive than in ‘real world’ patients,
which has resulted in the idea that the majority of patients
recover over a relatively short time span and that only a
minority has a chronic course. Although the clinical
course of MDD has been an extensive topic of debate, re-
search outcomes have generally given rise to an optimistic
view. Moreover, this has translated into correspondingly
optimistic communication with patients and into clinical
management that aims for relatively short and episode-
oriented treatments.
Although MDD may indeed be limited to a single epi-
sode in some patients, Judd et al. [9] have shown that
most patients move in and out of more or less severe
levels of symptoms over time. This suggests that, given a
longer time frame, the prognosis is less favourable and
that studies with a short follow-up time or relatively few
assessments will tend to underestimate the prognosis of
MDD. Further, although depression, bipolar disorder and
anxiety disorders are conceptualised as distinct disorder
groups, they are closely related in terms of genetics [10]
and etiology, such as shared risk factors (e.g. childhood
trauma and negative life events [11]) and similar physio-
logical dysregulations [12]. Moreover, comorbidity levels
are as high as 75% [13]; thus, taking into account anxiety
disorders into the prognosis of MDD is extremely signifi-
cant from the patients’ perspective. Finally, the three diag-
nostic constructs overlap in treatment outcomes and
prognosis [14, 15]. Consequently, studies on the longitu-
dinal course of MDD that do not take comorbidity into
account might incline towards outcomes that are actually
unrealistically favourable [16, 17]. Persons who have re-
covered from MDD and are labelled as such might still
meet the full criteria of another, related psychiatric
disorder and thus still suffer from marked functional im-
pairment. It is therefore important, especially from the pa-
tients’ perspective, to consider the impact of other
frequently co-occurring disorders, such as dysthymia,
(hypo)mania and anxiety, when examining the full clinical
course of MDD.
In this paper, using data from the Netherlands Study of
Depression and Anxiety (NESDA), an on-going longitu-
dinal psychiatric cohort study ideally designed to examine
the long-term course of depressive and anxiety disorders
[18], we test the idea that the course of patients with
MDD changes seriously when different clinically meaning-
ful course perspectives are considered. We examine the
clinical course of MDD, expanding the perspective in
terms of (1) a longer time frame and (2) a broader
diagnostic conceptualisation including symptoms of
closely related affective and anxiety disorders, thereby
moving from a short, narrow course perspective to a long,
broad course perspective. MDD might have a less
favourable prognosis if one looks beyond diagnostic
boundaries, which would warrant a change in our com-
munication with patients and clinical management.
Methods
Study sample
Data were retrieved from NESDA [18], which, at baseline
(2004–2007), consisted of 2981 persons aged between 18
and 65 years, recruited from community (19%), primary
care (54%) and specialised mental healthcare (27%). The
sampling frame was designed to represent the various de-
velopmental stages of depressive and anxiety disorders, and
included patients with current or remitted depressive and/
or anxiety disorder (74%) and healthy controls (26%).
Exclusion criteria were (1) insufficient command of the
Dutch language and (2) a primary clinical diagnosis of other
severe psychiatric conditions such as bipolar disorder and
schizophrenia. The study was approved by the Ethical
Review Board of participating centres and all participants
signed informed consent. Every 2 years, face-to-face follow-
up assessments were conducted, with a response rate of
87.1% (n = 2596) at 2 years, 80.6% (n = 2402) at 4 years, and
75.7% (n = 2256) at 6 years. If participants missed an in-
between follow-up assessment they were assessed over the
time period since the last assessment.
At baseline, a diagnosis of MDD was assessed with
the DSM-IV Composite International Diagnostic
Interview (CIDI) version 2.1 [19]. A total of 1115 par-
ticipants were diagnosed with an MDD episode, of
any duration, during the 6 months prior to baseline
(i.e. a 6-month diagnosis). Depressive symptoms in
the week prior to assessment were measured with the
Inventory of Depressive Symptomatology (IDS) self-
report and were considered clinically relevant if the
score was more than 13 [20].
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The present study sample included 903 patients who
had a current 6-month MDD diagnosis with clinically
relevant depressive symptoms at baseline, and who had
at least one follow-up assessment available. Compared
to those with a 6-month MDD diagnosis that were ex-
cluded (total n = 212) because of low IDS score (n = 70)
or no follow-up (n = 142), the included sample was older
(P = 0.002), but was similar with respect to sex and years
of education. Follow-up information was available for
903 participants at 2 years, 811 participants at 4 years
and 712 participants at 6 years, providing an overall of
3329 observations.
Sample descriptive characteristics
Age, sex and years of education were assessed during
the baseline interview. Age at onset of MDD and
whether the baseline episode was a first or recurrent
MDD episode were derived from the CIDI. The severity
of depressive and anxious symptoms in the week prior
to assessment were examined using the IDS and the
Beck Anxiety Inventory (BAI) – Self Report [21], re-
spectively. Medications used in the month prior to base-
line were registered according to the World Health
Organization Anatomical Therapeutic Chemical classifi-
cation [22]. Selective serotonin reuptake inhibitors
(N06AB), tricyclic antidepressants (N06AA) and other
antidepressants (N06A, not N06AA, not N06AB) were
considered antidepressant treatment. Psychological treat-
ment was considered received if at least three sessions
provided by a healthcare professional were reported for
the prior 6 months, as measured with the Trimbos/iMTA
questionnaire for Costs associated with Psychiatric Illness
[23]. Treatment was categorised as present (antidepressant
and/or psychological treatment) or absent. A current
comorbid diagnosis of dysthymia and/or anxiety
disorder (social phobia, panic disorder, agoraphobia,
generalised anxiety disorder (GAD)) was assessed with
the CIDI [19].
Course trajectories
Course trajectories were determined using two sources
of data collected during each 2-year follow-up assess-
ment, namely (1) the CIDI and (2) the Life Chart
Interview (LCI) [24], and by joining data from all follow-
up assessments into a continuous record. The CIDI
determined the presence of DSM-IV classified MDD,
dysthymia, (hypo)mania symptoms and anxiety disorders
during each 2-year follow-up. For all patients with a
depressive, (hypo)mania or anxiety disorder diagnosis ac-
cording to the CIDI interview, information on the LCI
was considered. The LCI uses a calendar method,
wherein life-events were recalled to refresh memory,
after which the presence of at least mild depressive,
(hypo)mania, anxious and/or avoidance symptoms –
separately – at each month during the 2-year follow-up
was determined. The proportion of time with symptoms
(=duration) was calculated for each 2-year interval by
dividing the number of months with symptoms by the
total number of months between two assessments. An
episode was considered chronic if a person had a diag-
nosis on the CIDI in the 6 months prior to assessment
and consistent symptoms for a minimum of 2 years
(≥85% of time) on the LCI. If a person experienced only
one disorder (e.g. MDD), the duration of only that dis-
order (e.g. depressive symptoms) was taken into account.
If a person experienced multiple disorders (e.g. MDD
and GAD), symptom duration of these disorders (e.g. de-
pressive and/or anxiety symptoms) were integrated.
Symptom durations acquired by the LCI were thus only
considered in the presence of a CIDI-diagnosed
disorder.
Subsequently, we classified four course trajectories de-
scribing the course at three time points (2-, 4- and 6-
year follow-up):
1. Recovered: no diagnosis at 2-year follow-up or
thereafter;
2. Recurrent, without chronic episodes: one or more
diagnoses after baseline, but never a chronic episode;
3. Recurrent, with chronic episodes: one or more
diagnoses after baseline and at least one chronic
episode, but not at every follow-up assessment;
4. Consistently chronic: a diagnosis is consistently
present, a chronic episode at every follow-up
assessment.
These course trajectories were described from three
diagnostic perspectives, namely (1) MDD only, (2)
affective disorders (MDD, dysthymia and (hypo)mania)
and (3) affective and anxiety disorders (MDD, dysthymia,
(hypo)mania, panic disorder, agoraphobia, social phobia
and GAD). In total, this resulted in a stepwise comparison
of the prognosis, stepping up in time (three follow-up
periods) and broadening the diagnostic conceptualisation
by including affective and anxiety disorders (three diag-
nostic perspectives).
Clinical validation characteristic
To test concurrent functional impairment we compared
the level of disability of the four course trajectories at
each assessment within the long, broad perspective
(6-year follow-up, all affective and anxiety disorders, for
n = 712 participants). Disability was measured with the
World Health Organization Disability Assessment
Schedule II (WHODAS-II) [25] at all assessments. We
included all subscales except for the 4-item work disabil-
ity (total 32 items) to avoid missing answers due to
MDD patients often not working.
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Statistical analyses
Sociodemographic and clinical characteristics were re-
ported as percentages, or means and standard deviations
(SD). Occurrence of specific diagnoses, and the total
time spent with depressive, anxious, avoidance and
(hypo)mania symptoms, regardless of whether a CIDI
diagnosis was present, between baseline and 2-year,
baseline and 4-year, and baseline and 6-year follow-up
were reported as percentages.
The proportion of patients categorised in the de-
fined course trajectories were presented in nine differ-
ent pie charts reflecting the time by diagnostic
perspectives. As a clinical validation of the course
trajectories, the longitudinal association between
disability scores (WHODAS-II) and the four course
trajectories according to the long, broad perspective
(6-year follow-up, all affective and anxiety disorders;
n = 712; observations = 2661) was estimated using a
linear generalised estimating equations (GEE) model
(with an exchangeable correlation structure), account-
ing for within person correlation of repeated mea-
sures and missing observations. The GEE model
included a categorical time variable indexing the as-
sessment wave and was additionally adjusted for base-
line age, sex and years of education. Analysis was
conducted using SPSS version 22.0 [26].
Results
At baseline (Table 1), the mean age of the study sam-
ple was 41.4 years (SD = 12.0), 67% was female, and
both the average scores on depressive and anxiety
symptoms were indicative of moderate severity [27].
Additionally, more than two-thirds (70.9%) had at
least one comorbid disorder at baseline.
During 2 years of follow-up (Table 2), the recurrence
of MDD was 63.2% and 60.5% of patients had at least
one other disorder. Over the entire 6 years of follow-up,
the recurrence of MDD (after baseline) increased to
77.1% and 74.2% of participants had at least one other
disorder.
Further, over the 6 years of follow-up, a substantial
proportion of patients spent more than 75% of the
time with depressive (19.4%), anxious (18.7%) or
avoidance (10.3%) symptoms, while this proportion
was considerably lower for (hypo)mania symptoms
(0.1%) (Table 3).
The course of MDD
Figure 1 presents nine different pie charts showing the
proportions of patients classified in the defined course
trajectories for each of the three time points
(columns) and each of the three diagnostic perspec-
tives (rows).
To what extent does follow-up period impact the course of
MDD?
The first row of Fig. 1 shows that, at 2-year follow-up,
58% of the baseline MDD patients had recovered from
MDD, while 21% had recurrent MDD episodes and a
further 21% had a chronic MDD episode (Fig. 1a).
However, examining Fig. 1b and c shows that sustained
recovery rates dropped to 41% and 32% at 4- and 6-year
follow-up, respectively. Moreover, 34% (28.9 + 4.6) of
patients had chronic MDD episodes of at least 2-years
duration at the 6-year follow-up (Fig. 1c). A similar
decrease in recovery rates and increase in proportion of
patients with chronic episodes is observed in the second
(Fig. 1d–f ) and third rows (Fig. 1g–i).
To what extent does a broader diagnostic conceptualisation
impact the course of MDD?
Examining the first column of Fig. 1 reveals that full re-
covery rates at 2-year follow-up decreased from 58%
when considering only MDD (Fig. 1a) to 53% when in-
cluding dysthymia and (hypo)mania symptoms (Fig. 1d).
Only 37% of the baseline MDD patients remained fully
recovered when additionally considering comorbid
anxiety (Fig. 1g). A similar pattern was observed at 4-
(Fig. 1b, e, h) and 6-year follow-up (Fig. 1c, f, i).
Table 1 Descriptive characteristics of patients at baseline (n = 903)
Sociodemographics
Age, years, mean (SD) 41.4 (12.0)
Female sex, % (n) 67.0 (605)
Education, years, mean (SD) 11.6 (3.2)
Clinical characteristics
Age at onset of major depressive disorder, years,
mean (SD)
27.3 (12.6)
Recurrent episodes, yes, % (n) 52.6 (475)
Severity of depressive symptoms (IDS), mean (SD) 33.9 (10.9)
Severity of anxiety symptoms (BAI), mean (SD) 18.6 (10.9)
Treatment (antidepressants and/or psychotherapy), % (n) 62.8 (567)
Recruitment setting Community, % (n) 8 (72)
Primary care, % (n) 37.5 (339)
Specialised mental healthcare, % (n) 54.5 (492)
Current comorbiditya Dysthymia, % (n) 24.1 (218)
Generalised anxiety disorder, % (n) 30.2 (273)
Social phobia, % (n) 35.5 (321)
Panic disorder, % (n) 35.0 (316)
Agoraphobia, % (n) 30.0 (271)
Any other diagnoses, % (n) 70.9 (640)
aCurrent comorbidity = diagnosis present in 6 months prior to baseline;
patients with comorbid disorders appear in more than one diagnosis group
BAI Beck Anxiety Inventory, IDS Inventory of Depressive Symptomatology,
n number, SD Standard Deviation
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To what extent does the combination of both follow-up
and broader diagnostic conceptualisation impact the course
of MDD?
Examining only MDD over 2 years (the shortest, most
narrow perspective; Fig. 1a) suggests a relatively benign
prognosis, wherein 58% of patients recovered from MDD
and 21% had a chronic episode. However, employing a lon-
ger time frame (6 years) and broadening the conceptualisa-
tion of affective and anxiety disorders (including dysthymia,
(hypo)mania and anxiety disorders) (longest, broadest per-
spective, Fig. 1i) suggest a much less favourable prognosis,
with only 17% of patients having early and sustained
recovery and over 55% (40.6 + 14.7) with chronic episodes
(Fig. 1i).
Additional file 1: Figure S1 showed that including only
patients with complete data at all follow-up assessments
(n = 712) did not change the above results as overall
findings and percentages were very comparable.
Clinical validity of course trajectories
Figure 2 showed the raw mean disability (WHODAS-II)
scores at baseline and at 2-, 4- and 6-year follow-up for
the four course trajectories according to the long, broad
perspective. Within all groups, the average disability was
most severe at baseline, when all persons were in current
episodes. GEE analysis adjusted for age, sex and years of
education confirmed that, compared to those who
recovered in the first 2 years and remained free of affective
and anxiety disorder episodes until the 6-year follow-up,
disability was consistently higher in patients with ‘recurrent
without chronic episodes’ (B = 5.3, SE = 1.1, P < 0.001), in
patients with ‘recurrent with chronic episodes’ (B = 14.1,
SE = 1.0, P < 0.001) and in those with a ‘consistently
chronic’ trajectory (B = 21.3, SE = 1.4, P < 0.001) over
6 years. This supports the clinical validity of the four course
trajectories by indicating that the course groups not only
differ in terms of symptoms but also in terms of general
functioning.
Discussion
This study tested the idea that the clinical course of pa-
tients with MDD may be underestimated when a narrow
perspective is used with respect to either the time frame
or the diagnostic conceptualisation. Considering a long
and rigorous follow-up in a large cohort of patients with
MDD reveals that we may need to reconsider our concep-
tualisation of MDD. Including symptoms of closely related
disorders, such as (hypo)mania and anxiety symptoms,
shows that the majority of patients have a disabling and
chronic depressive disorder. Conceptualising MDD as a
narrowly defined and episodic disorder may underesti-
mate both the prognosis for the majority of our patients
and, consequently, the type of care that is appropriate.
With a short, narrow perspective (2-year follow-up and
MDD only), 58% of patients appeared recovered and only
a minority (21%) had a chronic episode. With a long,
broad perspective (6-year follow-up, including affective
and anxiety disorders) the recovery rate decreased to 17%
and the proportion of patients with chronic episodes in-
creased to 55%. The impact on the daily functioning was










Diagnoses % (n) % (n) % (n)
MDD 63.2 (571) 72.3 (586) 77.1 (549)
Dysthymia 27.0 (244) 33.5 (272) 38.2 (272)
Generalised anxiety
disorder
17.6 (159) 27.1 (220) 33.3 (237)
Social phobia 26.9 (243) 32.6 (264) 35.5 (253)
Panic disorder 22.4 (202) 28.1 (228) 32.2 (229)
Agoraphobia 21.3 (192) 26.0 (211) 28.2 (201)
(Hypo)manic symptoms 8.2 (74) 10.0 (81) 11.4 (81)
Any other diagnoses
(excluding MDD)
60.5 (546) 69.3 (562) 74.2 (528)
aPatients with comorbid disorders appear in more than one diagnosis group
MDD major depressive disorder










Symptoms % % % %
Percentage of time with symptoms during 0 to 2-year follow-upa
(n = 903)
Depressive symptoms 40.4 14.4 8.2 36.9
Anxiety symptoms 44.4 10.0 8.0 37.5
Avoidance symptoms 70.3 4.3 3.4 21.8
(Hypo)manic
symptoms
98.1 0.3 0.2 1.3
Percentage of time with symptoms during 0 to 4-year follow-upa
(n = 811)
Depressive symptoms 38.1 18.0 20.1 23.2
Anxiety symptoms 35.9 17.8 21.6 24.3
Avoidance symptoms 61.4 8.0 17.4 12.7
(Hypo)manic
symptoms
97.8 1.2 0.6 0.4
Percentage of time with symptoms during 0 to 6-year follow-upa
(n = 712)
Depressive symptoms 35.5 27.1 17.1 19.4
Anxiety symptoms 32.3 27.4 21.1 18.7
Avoidance symptoms 57.2 19.4 12.6 10.3
(Hypo)manic
symptoms
97.6 1.7 0.6 0.1
aTime spent with symptoms regardless whether CIDI diagnoses present
Verduijn et al. BMC Medicine  (2017) 15:215 Page 5 of 9
found to be parallel to the severity of the course
trajectory.
The current findings suggest that we may need to re-
think the conceptualisation of depression from an epi-
sodic and isolated disorder to a recurrent and often
chronic disorder with high levels of comorbidity. Since
the nineteenth century, depression has been charac-
terised in numerous ways. In 1883, Clouston was one of
the first to describe melancholia with its symptoms [28].
This was further elaborated by Kraepelin [28, 29], who
advocated more emphasis on prognosis, functional con-
sequences or aetiology. Although DSM-5 [30] has be-
come more sensitive to both the development of
affective disorders over time and the inclusion of symp-
toms of co-occurring disorders, healthcare systems and
treatment protocols generally still conceptualise MDD as
relatively short-term and episodic. Moreover, lay people
tend to view depression as an incident in response to life
stress rather than a disorder that is often chronic [31].
Additionally, several studies on the prospective long-
term course of depression in the general population and
primary care describe high rates of stable recovery from
depressive symptoms (35–60%) [15]. The current study,
however, found that recovery rates were considerably
lower when relevant co-morbidity is included.
Consequently, this suggests that approaching depression
as a recurrent, but mostly ‘time-limited’, episodic dis-
order may amount to an underestimation of its severity
and clinical burden. We showed that only a minority of
depressed patients experienced early and sustained re-
covery from all affective and anxiety conditions, while
the majority experienced a pattern of recurrent and
often chronic episodes. The long-term impact that such
clinical courses have on a person’s level of functioning
Fig. 1 Pie charts of the course trajectories over 2-, 4- and 6-year follow-up for the different diagnostic categories
Verduijn et al. BMC Medicine  (2017) 15:215 Page 6 of 9
was confirmed by our clinical validation, where patients
with chronic episodes had consistently higher disability
levels compared to those without chronic episodes and
those that recovered.
Currently, psychiatric disorders are strictly cate-
gorised to limit overlap and increase specificity. How-
ever, in a recent review paper [32], Kendler showed
that the large majority of descriptions of major de-
pression up until the 1960s included anxiety as a
symptom of depression. In line with this, our results
suggest that depression and anxiety are not entirely
separate constructs. The high levels of co-occurrence
[13, 33], overlapping etiologies [10, 12] and similar
treatments that are effective for depression and
anxiety further support this. Our data suggest that in-
cluding co-occurring anxiety yields a more valid, al-
beit less favourable, picture of the prognosis of
depression. As in other areas in medicine, where the
prognosis of disorders is often chronic, such as in
rheumatoid arthritis, diabetes or chronic lung disor-
ders, we may need to shift our attention more to the
functional consequences of disorders when conceptualis-
ing the prognosis and testing interventions. Using the
DSM-5 instrument for functioning, our data suggest that
a broader and longer-term perspective of the prognosis of
affective disorders is ecologically and clinically relevant.
Our findings suggest that clinicians should consider inter-
ventions aimed at treating MDD as a chronic disorder and
should more systematically incorporate relapse prevention
strategies. Treatment should further focus on recovery
from multiple symptom domains (including, for example,
anxiety and hypomania) as well as functional recovery.
Moreover, clinical trials should aim to include a represen-
tative and ecologically valid study sample [8].
Our study is unique in that we have access to a large
cohort of patients representing the full range of depres-
sion and anxiety disorders. Patients were rigorously diag-
nosed and followed up over a longer period of time.
Information was available throughout the 6-year follow-
up period, allowing us to reliably categorise different
course trajectories. However, some limitations of this
study should also be noted. First, categorisation of the
heterogeneous prognosis into four course trajectories
inevitably results in arbitrary decisions for some cases,
especially those with missing information on the life-
chart. However, we showed that exclusion of those with
missing information did not change the results substan-
tially (Additional file 1: Figure S1). In our definition of
the course trajectories, duration of (mild) symptomatol-
ogy was not considered without the presence of a full
diagnosis. Hence, this definition of the course trajector-
ies might have underestimated the chronicity. Second,
information on comorbidity was considered for a limited
number of disorders. It would have been informative to
further include symptomatology of other psychiatric dis-
orders (e.g. obsessive compulsive disorder or substance
use disorders) into account. This may even further im-
pact on an unfavourable prognosis, but is beyond the
focus of our current paper in which we decided on the
most common affective and anxiety disorders that are
closely linked with MDD in terms of overlap in etiology,
symptomatology and treatment indications. Further, a
subset of our sample was aged above 60 years (18.7% at
6-year follow-up) and consequently may have somatic
morbidity, which could have attenuated the likelihood of
sustained recovery. Third, it should be noted that the
observational design of our study is not ideal to draw
conclusions regarding treatment. This study does not
Fig. 2 Mean disability scores (WHODAS) over time of the four course trajectories according to the longest, broadest perspective (6-year follow-up;
all affective and anxiety disorders; Fig. 1i) (n = 712)
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address the impact of specific treatments on the progno-
sis of MDD. It would, naturally, be of great importance
for future research to examine whether specific and
carefully delivered treatment could impact outcomes
more profoundly. Nevertheless, our results do show that,
despite the fact that the mental healthcare system in the
Netherlands is accessible, affordable and of good quality
[34], outcomes are generally unfavourable. Fourth, the
NESDA study commenced (2004) prior to the appear-
ance of DSM-5, and therefore diagnoses in this paper
reflect DSM-IV categories – of which some are no lon-
ger present in DSM-5 (e.g. dysthymia). Finally, during
follow-up, there was selective loss of patients. Since
those who are lost to follow-up are generally the worst
affected cases, selective loss tends to decrease the num-
ber of cases that would be classified as chronic at later
follow-up; therefore, our results might underestimate
the severity of the course.
Conclusion
Our data suggest that we may need to reconsider the
prognosis of patients with MDD. Including symptoms of
closely related disorders, such as (hypo)mania and
anxiety, shows that the majority of patients have a disab-
ling and chronic affective disorder and that full recovery
is the exception rather than the rule. Conceptualising
MDD as a narrowly defined and episodic disorder may
underestimate both the prognosis of the majority of our
patients and the type of care that is appropriate.
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